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showed that short-term pronase digestion of BT474 cells produced two HER2 fragments (of 95 and 150 kDa, detectable in tissue specimens as well), increased the binding affinity of trastuzumab,
Introduction
The human proto-oncogene HER2 encodes for the full-length membrane-spanning receptor p185 HER2 . The overexpression of p185 HER2 plays a pathogenic role in approximately 20% of breast cancers [1] . The large 110 kDa extracellular domain (ECD) of HER2 consists of 621 amino acids and is subdivided into four domains (I-IV) [2, 3] . The HER2 ECD constitutively adopts an active extended conformation, which is acquired by other EGFRs only after ligand binding. This structural feature of ECD favours the homo-and hetero-dimerisation of HER2, thus encouraging activation of the intracellular tyrosine kinase domain and triggering downstream signalling events [4] .
Pertuzumab, a humanised monoclonal antibody, binds to HER2 near the centre of domain II and inhibits HER2 dimerisation with other members of the EGFR family [5, 6] . In contrast, binding of trastuzumab to domain IV of HER2 does not interfere with heregulin-induced HER2-HER3 dimer formation but prevents HER2 shedding and inhibits intracellular signalling [7] .
Approximately 30% of HER2-positive patients express a variety of receptor fragments sized between 90 and 115 kDa. These are collectively known as p95 HER2 carboxy-terminal fragments (CTF) [8] . In breast cancer, HER2-CTFs may be synthesised [9, 10] or produced by an enzymatic sheddase [11] . A slow proteolytic cleavage performed by metalloproteases can occur at a site proximal to the transmembrane domain [12] [13] [14] thus generating a fragment of 95 kDa that retains kinase activity [15] [16] [17] [18] [19] . It is yet to be determined whether p95 HER2 levels in breast tumours are directly linked to the HER2 concentration in the serum [20] [21] [22] . The rapid and potent shedding of HER2 ECD produced in vitro by pervanadate [23] , a general inhibitor of protein-tyrosine phosphatases with a non-specific metalloprotease activation capacity, induces an increase in p95 HER2 levels in BT474 breast cancer cells and delivers the trastuzumab epitope to the cell culture medium [16] . Scaltriti et al. [14] hypothesised that the tumours expressing p95 HER2 in the absence of the trastuzumab-binding extracellular domain may be resistant to the humanised antibody.
However, a translational investigation from the neoadjuvant GeparQuattro study (incorporating 5 chemotherapy plus trastuzumab treatment) showed that p95 HER2 expression, measured using a monoclonal antibody that specifically recognises the 611 CTF by immunohistochemistry (IHC),
indicates a response to trastuzumab [24] .
In previous studies using biotinylated trastuzumab (BiotHER) as the primary antibody for IHC [25, 26] , we demonstrated that the trastuzumab binding site was only detectable in approximately 50%
of HER2 amplified breast cancers, while the reported percentage of HER2 overexpression using anti-intracellular domain (ICD) antibodies in amplified breast cancers is approximately 90% [27] .
Similarly, we previously showed a lower percentage of ECD overexpression using the TAB250 antibody compared to the ICD expression as evaluated by CB11 in amplified breast cancers [28] .
Taken these data together, our hypothesis was that the expression of HER2 truncated forms could reduce the availability of the epitopes necessary for a reaction with specific anti-ECD antibodies. 
Material and Methods

Tissue Samples
Paired FFPE tissue blocks and snap frozen specimens (stored at -80°C in frozen tissue matrix OCT) from 99 breast cancers were obtained from the pathology files of the authors' institutions. The fixation was performed in buffered formalin at room temperature (RT) for 24-48 hr. Permission for the project was obtained from the Institutional Review Board, and the study was conducted in compliance with the ethical regulatory requirements for the handling of biological specimens from tumour banks of the participating institutions (i.e., samples were exclusively available for research 6 purposes in retrospective studies). The same institutional ethics review board agreed that written consent from the patients was not required, given that the study did not interfere with diagnosis or treatment decisions. The patient data were anonymised prior to analysis.
Fluorescence in situ hybridisation (FISH)
FISH was performed using probes for HER2 (17q12) and CEP17 (Vysis, Inc, Downers Grove, IL, USA) as previously reported [29] . The analysis was performed by selection and automated acquisition of six invasive areas on each slide using the Metafer Scanning System (Carl Zeiss
MetaSystems GmbH) and AxioImager epifluorescence microscope. The PathVysion V2 software (FDA approved) was used to analyse the results. The cases were scored according to the ASCO guidelines [30] .
Immunostaining
The expression of the ICD was evaluated using Herceptest blocks (control and test) were processed with the same IHC protocols reported above.
In vitro induction of p95
HER2
To induce p95 HER2 production in BT474, cells were treated with freshly prepared pervanadate (0. The cell growth was monitored in flasks with an EVOS inverted microscope (Advanced Microscopy Group, Bothell, WA), and cell viability was assessed using trypan blue vital staining.
Each experiment was performed in triplicate. The paraffin-embedded blocks were prepared from cell pellets obtained after fixation in buffered formalin.
Western blot (WB) analysis
After each treatment described above, the expression of HER2 was assessed by WB on BT474 The total protein extracts were quantified with the BCA protein assay (Thermo Fisher Scientific Inc, Rockford, IL, USA), divided into aliquots of 25 g and stored at -80°C.
After the addition of 5X loading buffer, each sample was boiled for 5 min and loaded onto an 8% polyacrylamide gel. Each gel contained a control lane loaded with 25 g of protein extracted from pervanadate-treated BT474 cells as marker for p95 HER2 .
Electrophoresis was performed in TGS buffer; after separation, proteins were transferred to a nitrocellulose membrane. After saturation with TBS and 5% milk, the membrane was immunoblotted either with anti-HER2 (A0485, polyclonal antibody Dako, Glosrup, Denmark) at 1:1000 or with anti-actin at 1:800 as a loading control. Both antibodies were diluted in TBS with 5% BSA and incubated overnight at 4°C. The membrane was washed and incubated with an antirabbit peroxidase-labelled secondary antibody. Finally, the membrane was developed with ECL luminol (Bio-Rad, Hercules, CA, USA). 
Flow cytometry
To obtain a single cell suspension, BT474 cells were detached with trypsin/EDTA and collected 
Immunoprecipitation analyses
The pronase-treated BT474 cells were lysed in RIPA buffer as described above. Total extract aliquots of 500 g were incubated with 2 g of trastuzumab or pertuzumab at 4°C overnight under gentle agitation. Twenty l of sepharose-protein A and sepharose-protein G beads were added.
After incubation for 2 hr at 4°C the sepharose beads were washed and rinsed with 1X loading buffer. The immunoprecipitated proteins and 25 g of control total extracts were analysed by western blot using the same protocol described above.
Proximity ligation assay (PLA)
All reagents used for the PLA analysis were from Olink Bioscience (Uppsala science park, 75183
Uppsala, Sweden). The PLA reactions were performed following the manufacturer's instructions using anti-HER2 (A0485 polyclonal diluted 1:300) and anti-HER3 (monoclonal antibody clone 6F12 diluted 1:100 Lab Vision, Thermo Fisher Scientific Inc, Kalamazoo, MI USA.) as primary antibodies. Student's t-test was used assuming unequal variances.
Results
Correlation of p95 HER2 and IHC results in breast cancer specimens
By WB analysis, p185 HER2 was detectable in 50 cases. Forty samples showed HER2 amplification by FISH. Among these amplified cases, 20 were p185 HER2 ++, and 12 of these also expressed p95 HER2 by WB (Figure 2 ). In the latter subgroup of cases, five showed a 150 kDa fragment as well. 
HER2-HER3 dimer dissociation
12
The PLA performed using anti-HER2 and -HER3 antibodies allowed for the analysis of heterodimers in BT474. The mean number of signals per cell (mean = 20.30; mode = 18; standard deviation = 10.53; n = 315) in the control was significantly higher (p < 0.005) as determined by a ttest analysis than the mean number of signals per cell (mean = 13.76; mode = 5; standard deviation = 9.88; n = 384) in the BT474 pronase-treated cells (Figure 11 ).
Discussion
Our first objective was to evaluate whether p95 HER2 may impair the trastuzumab-binding epitope.
Using WB and IHC analyses, we confirmed the results by Molina et al. [18] demonstrating that p95 HER2 fragments in breast cancer tissues are generally associated with high levels of p185 HER2 .
However, in contrast to our expectations, we observed that the IHC expression of the trastuzumab epitope as detected by BiotHER in breast cancer tissue was higher in p95 HER2 + cases compared to cases with similar high levels of p185 HER2 but negative for p95 HER2 . This result could explain the response of tumours that expressed p95 HER2 to trastuzumab therapy measured by IHC as shown in the neoadjuvant GeparQuattro study [24] .
A possible explanation for this unexpected increase in immunoreactivity of the anti-HER2
antibodies in the presence of truncated HER2 may be the reduction of the antigen "steric hindrance". It has been demonstrated that the number of antigen molecules that are bound to the cell surface could significantly affect the ability of antibodies to bind, causing a steric hindrance [32] . If the antigenic determinants are closely spaced on the cell surface, a spatial interference may result such that a smaller distance between the antigenic determinants leads to a greater likelihood of reduced antibody binding. In previous experiments Valabrega and colleagues [33] were able to modulate the expression of HER2 in SKBR3 HER2-overexpressing breast cancer cells by using small interfering RNAs at different concentrations. In agreement with our hypothesis, it was shown that a HER2 reduction up to 70%, as measured by WB analysis and flow cytometry, still 13 corresponded to an immunoreactivity of cells scored as 3+ and that HER2 reduction up to 40% rendered cancer cells more sensitive to trastuzumab treatment.
To study the effect of HER2 truncation in vitro, as suggested by others [16] , we used pervanadate, a protein-tyrosine phosphatase inhibitor that induces HER2 shedding in BT474 cells through nonspecific metalloprotease activity. Unfortunately, we found pervanadate to be highly toxic. An alternative method to test our hypothesis was to simulate proteolysis by treating cells directly with a proteases cocktail known as pronase, a mixture of at least 10 proteases [34] commonly used in IHC for antigen retrieval of FFPE tissues. Digestion using pronase-based solutions is designed to break the protein cross-links and unmask the antigens and epitopes in FFPE tissue sections, enhancing the antibody staining intensity [35] . In addition, pronase treatment of high molecular weight glycoproteins is a useful method for obtaining glycoprotein fragmentation without significant loss of biological activity [36] . We demonstrated that pronase treatment of BT474 cells led to a and prevent dimer formation [5, [37] [38] [39] . By WB we showed that the 150 kDa fragments is present in human breast cancer tissues as well.
The size of the antibody molecule (150 kDa for IgG) may be another source of interference, particularly if the epitopes are closely spaced. Thus, steric hindrance is likely to be intensified when the antibodies have been labelled with other molecules such as biotin. In our IHC tissue protocol, 14 the effect of trastuzumab biotinylation on the avidin-biotin reaction was controlled by using aminocaproate, which limits the steric hindrance by providing a six-carbon spacer to biotin and thus improves accessibility to the binding site on avidin.
In conclusion 
